Ranbaxy secures 10% stake in Nihon Pharma
By Pradeep Rane | 26 Sep 2002
Mumbai: Ranbaxy Laboratories has acquired a 10-per cent stake in Nihon Pharmaceutical Industry Co (NPI) from its parent, the Tokyo-based Nippon Chemiphar Co (NC).
Ranbaxy has entered into an agreement with NC and NPI in this regard, which would give the Indian company an access to the $50-billion pharmaceuticals market in Japan.
Ranbaxy, through its wholly-owned subsidiary Ranbaxy Netherlands BV, has also entered into a definitive agreement with NC and NPI to acquire from NC 10-per cent equity stake in NPI.
The wide-ranging business alliance envisages Ranbaxy, NC and NPI to work together to launch Ranbaxys ethical and drug delivery system-based products and generic products in Japan.
It will also help Ranbaxy to manufacture and launch NCs existing products in the overseas markets by leveraging research and development capabilities, apart from increasing the sales and distribution network of both the companies.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
